Ryder System, Inc. (R)

NYQ – Real Time Price. Currency in USD

227.76

-4.71 (-2.03%)

At close: May 12, 2026, 4:00 PM EDT

227.76

0.00 (0.00%)

After-hours: May 12, 2026, 5:42 PM EDT

05.05.2026

Theralase(R) Announces $4 Million Brokered LIFE Offering

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC" or the "Agent") to act as the sole agent and sole bookrunner on a commercially reasonable "best efforts" agency basis for a brokered private placement offering ("Offering") of units of the Company ("Units") at a price of C$0.24 per Unit, to raise a minimum of C$3,000,000 and up to a maximum of C$4,000,000 in aggregate gross proceeds. Each Unit will consist of one common share of the Company ("Common Share") and one Common Share purchase warrant ("Warrant").

05.05.2026

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) Chief Executive Officer John Diez will present a company update at the 2026 Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference. Who: Ryder System, Inc. Chief Executive Officer John Diez What: Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference When: Tuesday, May 12, 2026 Time: 11:05 a.m. Eastern Time Webcast: To access the link to the live webcast, visit: Ryder.

04.05.2026

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's audited consolidated financial statements for the twelve-month period ended December 31st, 2025 ("Financial Statements"). Theralase® will be hosting a conference call on May 12 th at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal year ending December 31st, 2025.

04.05.2026

Gelum Shares Approved for Trading on the OTCQB(R) Venture Market

Vancouver, British Columbia--(Newsfile Corp. - May 4, 2026) - Gelum Resources Ltd. (CSE: GMR) (OTCQB: GMRCF) ("Gelum" or the "Company") reports that the Company's common shares have been re-approved and admitted for trading on the OTCQB Venture Market under the symbol GMRCF commencing May 4, 2026.

02.05.2026

AminoQuest Labs(R) Launches New Research Platform and Expands Access to High-Purity Laboratory Peptides

New York, New York--(Newsfile Corp. - May 1, 2026) - AminoQuest Labs® (https://aminoquestlabs.com), a U.S.-based supplier of research peptides, today announced the official launch of its new online platform along with expanded capabilities to support laboratories and research professionals nationwide. The newly launched website provides streamlined access to research-grade peptide compounds, enhanced product documentation, and improved ordering functionality designed for scientific and laboratory use.

01.05.2026

Ryder Declares Quarterly Cash Dividend

MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder declares quarterly cash dividend.

01.05.2026

Rosy Used Vehicle Sales, Operational Discipline Aid Ryder's Prospects

R's upbeat used-vehicle sales, contractual growth and disciplined operations --- plus dividends and buybacks ---- boost its outlook as freight recovers.

Videos

No Data

There is no data to display

Press releases

05.05.2026

Theralase(R) Announces $4 Million Brokered LIFE Offering

05.05.2026

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

04.05.2026

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

04.05.2026

Ryder System, Inc. (R)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Ryder System, Inc. (R)

Theralase(R) Announces $4 Million Brokered LIFE Offering

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Gelum Shares Approved for Trading on the OTCQB(R) Venture Market

AminoQuest Labs(R) Launches New Research Platform and Expands Access to High-Purity Laboratory Peptides

Ryder Declares Quarterly Cash Dividend

Rosy Used Vehicle Sales, Operational Discipline Aid Ryder's Prospects

Videos

No Data

Press releases

Theralase(R) Announces $4 Million Brokered LIFE Offering

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Gelum Shares Approved for Trading on the OTCQB(R) Venture Market

Theralase(R) Announces $4 Million Brokered LIFE Offering

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Gelum Shares Approved for Trading on the OTCQB(R) Venture Market

AminoQuest Labs(R) Launches New Research Platform and Expands Access to High-Purity Laboratory Peptides

Ryder Declares Quarterly Cash Dividend

Rosy Used Vehicle Sales, Operational Discipline Aid Ryder's Prospects

Videos

No Data

Press releases

Theralase(R) Announces $4 Million Brokered LIFE Offering

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Gelum Shares Approved for Trading on the OTCQB(R) Venture Market

Search stocks

Ryder System, Inc. (R)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Ryder System, Inc. (R)

Theralase(R) Announces $4 Million Brokered LIFE Offering

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Gelum Shares Approved for Trading on the OTCQB(R) Venture Market

AminoQuest Labs(R) Launches New Research Platform and Expands Access to High-Purity Laboratory Peptides

Ryder Declares Quarterly Cash Dividend

Rosy Used Vehicle Sales, Operational Discipline Aid Ryder's Prospects

Videos

No Data

Press releases

Theralase(R) Announces $4 Million Brokered LIFE Offering

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Gelum Shares Approved for Trading on the OTCQB(R) Venture Market

Theralase(R) Announces $4 Million Brokered LIFE Offering

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Gelum Shares Approved for Trading on the OTCQB(R) Venture Market

AminoQuest Labs(R) Launches New Research Platform and Expands Access to High-Purity Laboratory Peptides

Ryder Declares Quarterly Cash Dividend

Rosy Used Vehicle Sales, Operational Discipline Aid Ryder's Prospects

Videos

No Data

Press releases

Theralase(R) Announces $4 Million Brokered LIFE Offering

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Gelum Shares Approved for Trading on the OTCQB(R) Venture Market